Burrill & Co. launches life sciences venture fund with $313 million in commitments

Firm is aiming for at least $500 by June 2012

Register for free to listen to this article
Listen with Speechify
SAN FRANCISCO—Burrill & Co. announced recently that Burrill Capital Fund IV L.P., which commencedoperations at the beginning of December, launched with aggregate capital commitments of $313 million
"We are pleased to have surpassed our initialgoal of $300 million in capital commitments for the first close," says G.Steven Burrill, CEO of Burrill & Co., a global life sciences financialservices firm. "We look forward to achieving our final goal of $500million in capital commitments by June 2012." 

The fund will invest globally in the lifesciences, including early- to late-stage investments in therapeutics,diagnostics, medical devices, healthcare delivery, wellness, and digitalhealth.
Founded in 1994, Burrill & Co. is adiversified global financial services firm focused on the life sciencesindustry. With more than $1 billion in assets under management, the firm'sbusinesses include venture capital, private equity, merchant banking, andmedia. Headquartered in SanFrancisco, the company oversees a global network of offices throughout theUnited States, Latin America, Europe, and Asia. For more information visit: .

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue